Glenmark Pharmaceuticals Limited — Updates, 30-01-2026: Press Release

Glenmark Pharma reported strong Q3 consolidated revenue up 15.1% to ₹3,900.6 Cr, and EBITDA jumped 44.9% to ₹869.7 Cr. A US regulator cleared the Monroe facility to restart production. A significant AbbVie partnership for ISB 2001 secured an upfront US$700 million (₹6,111.7 Cr) plus milestones, boosting its innovative portfolio.